Bristol-Myers Squibb Company

17 Archived Projects

Title Investigator
Start End
Sexual Behavior and HIV-1 Drug Resistance
Safety & Efficacy of Abatacept in Adults with Relapsing-Remitting Multiple Sclerosis Bluestone
Atripla Adherence and Resistance Relationships [II] Deeks
Determination of Reyataz (Atazanavir Sulfate) Levels in Hair: A New Assay and Possible Predictor for Long-Term Virologic Outcome Gandhi
BMS-790052 with Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Infected Subjects Who are Null or Partial Responders to Peginterferon Alfa plus Khalili
BMS-790052 with Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects with Chronic Hepatitis C Genotype 1 Khalili
Pegylated Interferon Lambda w/wo Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 Khalili
AI452-020-0092: Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered with Telaprevir in Subjects with Genotype-1 Chronic Hepatitis C who are Treatment-naïve or Re Khalili
Screening and Management of Chronic Hepatitis B Virus Infection: A Survey of San Francisco Health Care Providers Khalili
Host and Viral Predictors of Prediabetes in at-risk Latinos with Chronic Hepatitis C (HCV) Khalili
Host Genetic Predictors of IDO-induced Tryptophan Catabolism Among HIV-Infected Ugandans Maintaining Treatment-Mediated Viral Suppression Lee
Study of BMS-790052 plus Peg-Interferon alfa 2a and Ribavirin in Previously Untreated HCV Patients Coinfected with HIV and HCV Luetkemeyer
Entecavir Intensification for HIV-HBV Coinfected subjects with persistent HBV viremia Luetkemeyer
A Phase 2, Open-Label Study of Daclatasvir (BMS-790052) and TMC435 in Combination With or Without Ribavirin (RBV) For Treatment-Naive Subjects or Null Responders to Prior Peginterferon Alfa (PegIFN)/RBV Therapy with Genotype 1 Chronic Hepatitis C Luetkemeyer
Study Evaluating the Efficacy and Safety of Pegylated Interferon Lambda-1a, in Combination with Ribavirin and Daclatasvir for Treatment of Chronic HCV Infection with Treatment Naïve Genotypes 1, 2, 3 or 4 in Subjects Coinfected with HIV-1 Luetkemeyer
Protocol AI463-189-004: A Comparative Study of the Antiviral Efficacy and Safety of Entecavir (ETV) Rosenthal
Grant Agreement #27475 - AIDS 2031: UW-UCSF Research Symposium of HIV in Women Volberding